TransMedics 10-Q Discloses Inventory-Related Material Weakness Alongside Record Q3 Revenue
TMDX sits 37% above its 52-week low of $60.105 on elevated volume (2.0× avg).
Summary
TransMedics' Q3 10-Q confirms record revenue of $203.0 million and $17.1 million of net income already reported, but newly discloses a material weakness in inventory-related internal controls that leaves disclosure controls ineffective at September 30, 2026.
Key Events · Earnings and Guidance · TMDX
-
Material Weakness in Inventory Controls
Management concluded disclosure controls and procedures were not effective at September 30, 2026 because controls over inventory movement within the manufacturing network were not designed and maintained for interim periods.
-
Remediation Targeted by Year-End
New interim inventory counting, system-based and monitoring controls were implemented in the quarter ended June 30, 2026; management targets completing operating-effectiveness testing and remediation by December 31, 2026.
-
Q3 Profit Down Despite Record Revenue
Net income was $17.1 million, or $0.46 per diluted share, versus $24.3 million, or $0.66, a year ago, as operating expenses rose to $90.5 million from $61.3 million.
-
Cash Generation Halved Year Over Year
Nine-month operating cash flow was $77.8 million versus $158.3 million a year ago, with receivables up $28.1 million and inventory up $19.4 million; cash stood at $493.0 million.
Analysis · TMDX · Industrial Applications And Services
The headline numbers — record Q3 revenue of $203.0 million, up 41%, and net income of $17.1 million — were already out via the same-day 8-K. What is new in the 10-Q is the control environment: management concluded disclosure controls were not effective at September 30, 2026 because controls over interim inventory movement within the manufacturing network were not designed and maintained. That is a governance red flag on top of a quarter where operating expenses jumped to $90.5 million from $61.3 million and nine-month operating cash flow fell to $77.8 million from $158.3 million. Remediation controls were implemented in the June 2026 quarter, but operating-effectiveness testing is not expected to finish until the fourth quarter, so the weakness stays open into year-end. Cash of $493.0 million and a $460 million convertible note due 2028 keep liquidity comfortable, but the combination of rising spend, a large new headquarters finance lease and an unresolved control gap is what investors will weigh against the growth story.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, TMDX was trading at $82.50 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $2.4B. The 52-week trading range was $60.11 to $156.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.